Convenience or Necessity? The Formation of the Working Class in the Universidades Laborales of Franco’s Spain (1955-1978)

La política educativa franquista tuvo como uno de sus principales objetivos la formación de la clase obrera, por lo que una de las principales instituciones educativas creadas en la época fueron las Universidades Laborales. Este artículo se centra en analizar las finalidades que perseguían estas macroinstituciones al formar los futuros obreros españoles, empleando para su estudio diversas fuentes primarias —documentales, archivísticas, gráficas y jurídicas—. Las conclusiones señalan que los objetivos de las Universidades Laborales fueron, por un lado, la formación profesional especializada y, por el otro lado, su adoctrinamiento en los principios ideológicos propugnados por el régimen.One of the main objectives of Franco’s educational policy was the training of the working class, which is why one of the principal educational institutions created during that period were the Universidades Laborales. This article is focused on analyzing the ends sought by these macroinstitutions in preparing the future workers of Spain, and it makes use of a variety of primary sources —documentary, archival, graphic and juridical— in order to study the subject. The conclusions indicate that the objectives of the Universidades Laborales were, on the one hand, specialized professional training and, on the other hand, their indoctrination in the ideological principles advocated by the regime

Cirugía robótica en patología quirúrgica benigna y maligna (urología, cirugía general y digestiva, cirugía cardiotorácica, ginecología, endocrinología, oftalmología y cirugía de cabeza y cuello). Capítulo I: cirugía cardiotorácica, endocrina, oftalmológica y cirugía de cabeza y cuello

Cirurgia robòtica; Tècniques quirúrgiques; InnovacióCirugía robótica; Técnicas quirúrgicas; InnovaciónRobotic surgery; Surgical techniques; InnovationAquest estudi té l’objectiu de determinar si la cirurgia assistida per robot, quan aquesta és el tractament indicat en una sèrie de patologies benignes o malignes, ha de ser incorporada en la cartera comuna bàsica de serveis assistencials del SNS i, per tant, convertir-se en una tecnologia finançada a través de fons públics. Per fer-ho s’ha avaluat l’eficàcia o l’efectivitat, la seguretat i l’eficiència de la cirurgia assistida per robot en comparació amb la cirurgia oberta o endoscòpica en un grup d’indicacions de patologia benigna o maligna en les especialitats de cirurgia cardiotoràcica, endocrina, oftalmològica, de cap i coll.El estudio tiene el objetivo de determinar si la cirugía asistida por robot, cuando la cirugía es el tratamiento indicado en una serie de patologías benignas o malignas, debe ser incorporada en la cartera común básica de servicios asistenciales del SNS y, por tanto, convertirse en una tecnología financiada a través de fondos públicos. Para ello se ha evaluado la eficacia o la efectividad, la seguridad y la eficiencia de la cirugía asistida por robot en comparación con la cirugía abierta o endoscópica en un grupo de indicaciones de patología benigna o maligna en las especialidades de cirugía cardiotorácica, endocrina, oftalmológica y de cabeza y cuello.The aim of the report is to determine whether robot-assisted surgery —when surgery is the indicated treatment for a series of benign or malignant pathologies— should be included in the basic common portfolio of the SNS healthcare services and thus become a publicly funded technology. To this end, the efficacy or effectiveness, safety and efficiency of robot-assisted surgery has been evaluated in comparison with open or endoscopic surgery in a group of indications of benign or malignant pathology in the specialities of cardiothoracic surgery, endocrine surgery, ophthalmological surgery, head and neck surgery

Grupo español de cirugía torácica asistida por videoimagen: método, auditoría y resultados iniciales de una cohorte nacional prospectiva de pacientes tratados con resecciones anatómicas del pulmón

Introduction: our study sought to know the current implementation of video-assisted thoracoscopic surgery (VATS) for anatomical lung resections in Spain. We present our initial results and describe the auditing systems developed by the Spanish VATS Group (GEVATS). Methods: we conducted a prospective multicentre cohort study that included patients receiving anatomical lung resections between 12/20/2016 and 03/20/2018. The main quality controls consisted of determining the recruitment rate of each centre and the accuracy of the perioperative data collected based on six key variables. The implications of a low recruitment rate were analysed for '90-day mortality' and 'Grade IIIb-V complications'. Results: the series was composed of 3533 cases (1917 VATS; 54.3%) across 33 departments. The centres' median recruitment rate was 99% (25-75th:76-100%), with an overall recruitment rate of 83% and a data accuracy of 98%. We were unable to demonstrate a significant association between the recruitment rate and the risk of morbidity/mortality, but a trend was found in the unadjusted analysis for those centres with recruitment rates lower than 80% (centres with 95-100% rates as reference): grade IIIb-V OR=0.61 (p=0.081), 90-day mortality OR=0.46 (p=0.051). Conclusions: more than half of the anatomical lung resections in Spain are performed via VATS. According to our results, the centre's recruitment rate and its potential implications due to selection bias, should deserve further attention by the main voluntary multicentre studies of our speciality. The high representativeness as well as the reliability of the GEVATS data constitute a fundamental point of departure for this nationwide cohort

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer

Background and aim: In stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors have revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC. Relevance for patients: This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.Sin financiaciónNo data 2020UE

Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study

Background: Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage. Methods: In this non-inferiority, randomised, controlled, open-label, phase 3 trial (INSPIRE) recipients were aged 18 years or older and were registered as standard criteria primary double lung transplant candidates. Eligible donors were younger than 65 years old with a ratio of partial pressure of oxygen in arterial blood to the fraction of inspired oxygen of more than 300 mm Hg. Transplant recipients were randomly assigned (1:1) with permuted blocks, stratified by centre, to receive standard criteria donor lungs preserved in the OCS Lung device (OCS arm) or cold storage at 4\ub0C (control arm). The composite primary effectiveness endpoint was absence of PGD3 within the first 72 h after transplant and 30-day survival in the per-protocol population, with a stringent 4% non-inferiority margin. Superiority was tested upon meeting non-inferiority. The primary safety endpoint was the mean number of lung graft-related serious adverse events within 30 days of transplant. We did analyses in the per-protocol and intention-to-treat populations. This trial is registered with ClinicalTrials.gov, number NCT01630434. Findings: Between Nov 17, 2011, and Nov 24, 2014, we randomly assigned 370 patients, and 320 (86%) underwent transplantation (n=151 OCS and n=169 control); follow-up was completed in Nov 24, 2016. The primary endpoint was met in 112 (79\ub74%) of 141 patients (95% CI 71\ub78 to 85\ub78) in the OCS group compared with 116 (70\ub73%) of 165 patients (62\ub77 to 77\ub72) in the control group (non-inferiority point estimate 129\ub71%; 95% CI 12 1e to 121\ub70; p=0\ub70038; and superiority test p=0\ub7068). Patient survival at day 30 post-transplant was 135 (95\ub77%) of 141 patients (95% CI 91\ub70\u201398\ub74) in the OCS group and 165 patients (100%; 97\ub78\u2013100\ub70) in the control group (p=0\ub70090) and at 12 months was 126 (89\ub74%) of 141 patients (83\ub71\u201393\ub79) for the OCS group compared with 146 (88\ub71%) of 165 patients (81\ub78\u201392\ub78) for the control group. Incidence of PGD3 within 72 h was reported in 25 (17\ub77%) of 141 patients in the OCS group (95% CI 11\ub78 to 25\ub71) and 49 (29\ub77%) of 165 patients in the control group (22\ub78 to 37\ub73; superiority test p=0\ub7015). The primary safety endpoint was met (0\ub723 lung graft-related serious adverse events in the OCS group compared with 0\ub728 events in the control group [point estimate 120\ub7045%; 95% CI 12 1e to 0\ub7047; non-inferiority test p=0\ub7020]). In the intention-to-treat population, causes of death at 30 days and in hospital were lung graft failure or lung infection (n=2 for OCS vs n=7 for control), cardiac causes (n=4 vs n=1), vascular or stroke (n=3 vs n=0), metabolic coma (n=0 vs n=2), and generalised sepsis (n=0 vs n=1). Interpretation: The INSPIRE trial met its primary effectiveness and safety endpoints. Although no short-term survival benefit was reported, further research is needed to see whether the reduced incidence of PGD3 within 72 h of a transplant might translate into earlier recovery and improved long-term outcomes after lung transplantation. Funding: TransMedics Inc

Resultados de la estadificación clínica ganglionar mediastínica del cáncer pulmonar quirúrgico: datos de la cohorte prospectiva nacional del Grupo Español de Cirugía Torácica Videoasistida

Introducción: El objetivo del estudio es valorar el rendimiento diagnóstico de la tomografía computarizada (TC) y la tomografía por emisión de positrones (PET) en la estadificación clínica mediastínica del cáncer pulmonar quirúrgico según los datos de la cohorte prospectiva del Grupo Español de Cirugía Torácica Videoasistida (GEVATS). Métodos: Se han analizado 2.782 pacientes intervenidos por carcinoma pulmonar primario. Se ha estudiado el acierto diagnóstico en la estadificación mediastínica (cN2). Se ha realizado un análisis bivariante y multivariante de los factores que influyen en el acierto. Se ha estudiado el riesgo de pN2 inesperado en los factores con los que se recomienda una prueba invasiva de estadificación: cN1, tumor central o tamaño mayor de 3cm. Resultados: El acierto global de la TC y PET en conjunto es del 82,9% con VPP y VPN de 0,21 y 0,93. En tumores mayores de 3cm y a mayor SUVmax del mediastino, el acierto es menor, OR de 0,59 (0,44 - 0,79) y 0,71 (0,66 - 0,75), respectivamente. En el abordaje VATS el acierto es mayor, OR de 2,04 (1,52 - 2,73). El riesgo de pN2 inesperado aumenta con el número de los factores cN1, tumor central o tamaño mayor de 3cm: entre el 4,5% (0 factores) y 18,8% (3 factores), pero no hay diferencias significativas con la realización de prueba invasiva. Conclusiones: La TC y PET en conjunto tienen un elevado valor predictivo negativo. Su acierto global es menor en tumores mayores de 3cm y SUVmax del mediastino elevado, y mayor en el abordaje VATS. El riesgo de pN2 inesperado es mayor si cN1, tumor central o mayor de 3cm y no varía significativamente con prueba invasiva